Literature DB >> 3029156

Defects in insulin binding and autophosphorylation of erythrocyte insulin receptors in patients with syndromes of severe insulin resistance and their parents.

F Grigorescu, V Herzberg, G King, M Meistas, J Elders, T Frazer, C R Kahn.   

Abstract

Genetic forms of severe insulin resistance are often characterized by alterations in binding and/or kinase properties of the insulin receptor. To evaluate whether alterations in insulin receptor kinase of erythrocytes can be used as genetic markers, we studied patients with two apparently inherited conditions of severe insulin resistance (leprechaunism and the type A syndrome of insulin resistance) and their families. In the two propositi, [125I]insulin binding to intact erythrocytes was decreased by 64% and 45%, respectively. This was primarily due to a decrease in receptor number and was found in intact cells and solubilization of the receptors. Similar insulin binding defects were found on monocytes. Insulin-stimulated tyrosine kinase activity of the solubilized receptor from erythrocytes was also decreased and to a similar extent as binding. Parents of neither patient had clinical manifestations of leprechaunism or the type A syndrome. Furthermore, no alterations in insulin receptor binding or kinase activity were found in erythrocytes from the mothers. Insulin binding in the father of the type A patient was also normal, whereas the father of the leprechaun had decreased receptor affinity. Receptors extracted from the both fathers' cells had a 40-60% decrease in maximal insulin-stimulated phosphorylation and significant rightward shifts of the insulin dose-response curves (ED50, 141 and 42 ng/mL, respectively; control ED50, 16 ng/mL). The finding of biochemical defects in insulin receptor kinase activity in clinically unaffected parents of patients suggests that these alterations may be useful genetic markers and more sensitive than insulin binding studies for studying pattern of inheritance of these diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029156     DOI: 10.1210/jcem-64-3-549

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Defects in insulin binding and receptor kinase in cells from a woman with type A insulin resistance and from her family.

Authors:  Y Suzuki; N Hashimoto; F Shimada; M Taira; M Mimura; O Nozaki; M Tawata; T Onaya; H Makino; S Yoshida
Journal:  Diabetologia       Date:  1991-02       Impact factor: 10.122

Review 2.  The insulin receptor and the molecular mechanism of insulin action.

Authors:  C R Kahn; M F White
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

Review 3.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

4.  Fibroblasts from a leprechaun patient have defects in insulin binding and insulin receptor autophosphorylation.

Authors:  J A Maassen; M P Klinkhamer; G C van der Zon; H Sips; W Möller; H M Krans; D Lindhout; F A Beemer
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 5.  Lipoatrophic diabetes.

Authors:  H Dörfler; G Rauh; R Bassermann
Journal:  Clin Investig       Date:  1993-04

6.  Insulin receptor function in fibroblasts from patients with leprechaunism. Differential alterations in binding, autophosphorylation, kinase activity, and receptor-mediated internalization.

Authors:  S S Reddy; V Lauris; C R Kahn
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

7.  Epidermal growth factor receptor defects in leprechaunism. A multiple growth factor-resistant syndrome.

Authors:  S S Reddy; C R Kahn
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

8.  Monoclonal antibodies to the insulin receptor stimulate the intrinsic tyrosine kinase activity by cross-linking receptor molecules.

Authors:  R M O'Brien; M A Soos; K Siddle
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.